Resumen de acción HZNP
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Horizon Therapeutics Public Limited Company
Historial de precios y rendimiento
Historical stock prices | |
---|---|
Current Share Price | US$116.30 |
52 Week High | US$116.38 |
52 Week Low | US$60.03 |
Beta | 1.01 |
1 Month Change | 0.76% |
3 Month Change | 12.37% |
1 Year Change | 82.80% |
3 Year Change | 45.18% |
5 Year Change | 505.10% |
Change since IPO | 1,171.04% |
Noticias y actualizaciones recientes
Recent updates
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely
Nov 25Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?
Nov 02Horizon pays HemoShear milestone payment under pact to develop gout therapies
Sep 21Horizon Therapeutics announces $500M buyback program
Sep 09Horizon Therapeutics to expand footprint in Ireland
Aug 29Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?
Aug 22Horizon Therapeutics: This Core Biotech Company Is On Sale
Aug 19Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)
Aug 04Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?
Aug 02Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth
Jul 31Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout
Jul 08Rentabilidad de los accionistas
HZNP | US Biotechs | Mercado US | |
---|---|---|---|
7D | 0.06% | 2.7% | 0.3% |
1Y | 82.8% | 2.9% | 24.2% |
Rentabilidad vs. Industria: HZNP superó al sector US Biotechs , que obtuvo un rendimiento del -3.7% el año pasado.
Rentabilidad vs. Mercado: HZNP superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.
Volatilidad de los precios
HZNP volatility | |
---|---|
HZNP Average Weekly Movement | 2.0% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: HZNP no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de HZNP (2%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
Fundada | Empleados | CEO | Página web |
---|---|---|---|
2005 | 2,190 | Tim Walbert | www.horizontherapeutics.com |
Resumen de fundamentos de Horizon Therapeutics Public Limited Company
Estadísticas fundamentales de HZNP | |
---|---|
Capitalización bursátil | US$26.63b |
Beneficios(TTM) | US$438.00m |
Ingresos (TTM) | US$3.64b |
60.8x
Ratio precio-beneficio (PE)7.3x
Ratio precio-ventas (PS)¿Está HZNP sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
Cuenta de resultados (TTM) de HZNP | |
---|---|
Ingresos | US$3.64b |
Coste de los ingresos | US$824.98m |
Beneficio bruto | US$2.82b |
Otros gastos | US$2.38b |
Beneficios | US$438.00m |
Últimos beneficios comunicados
Jun 30, 2023
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) | 1.91 |
Margen bruto | 77.36% |
Margen de beneficio neto | 12.02% |
Ratio deuda/patrimonio | 48.2% |
¿Cómo se ha desempeñado HZNP a largo plazo?
Ver rendimiento histórico y comparativa